Cargando…

Section 3. A Discussion of Flexible Dosing and Patient-Centered Therapy: Highlights of the Asthma Summit 2009: Beyond the Guidelines

Despite positive clinical experience and the published clinical benefits of monotherapy with low-or medium-dose inhaled corticosteroids or combination therapy with ICS + long-acting beta-agonist to treat asthma, many patients remain suboptimally controlled. Alternative approaches are needed, and 3 o...

Descripción completa

Detalles Bibliográficos
Autores principales: Canonica, G Walter, Brightling, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651139/
https://www.ncbi.nlm.nih.gov/pubmed/24228889
http://dx.doi.org/10.1097/WOX.0b013e3181d27cd8
Descripción
Sumario:Despite positive clinical experience and the published clinical benefits of monotherapy with low-or medium-dose inhaled corticosteroids or combination therapy with ICS + long-acting beta-agonist to treat asthma, many patients remain suboptimally controlled. Alternative approaches are needed, and 3 options that have had some success are: 1) using the patient's level of inflammation by established biomarkers to set treatment; 2) self-management incorporating flexible dosing; and 3) using a single inhaler for rescue and maintenance therapy. Which strategy for which patient depends ultimately on the individual patient's disease burden, life-style, comorbidities, preferences, and his or her ability to self-manage the disease, including assessing symptoms and adhering with therapy.